Phase I/II study of CTLA-4 inhibitor AGEN1884 1 PD-1 Inhibitor AGEN2034 in patients with advanced/refractory solid tumors, with expansion into 2L cervical cancer and solid tumors

被引：0

作者：

Coward, J. ^{[1
]}

Lemech, C. ^{[2
]}

Meniawy, T. ^{[3
]}

Dupont, C. D. ^{[4
]}

Gonzalez, A. M. ^{[5
]}

Lim, M. ^{[6
]}

Savitsky, D. ^{[4
]}

Carini, M. ^{[7
]}

Hu, S. ^{[8
]}

Shebanova, O. ^{[9
]}

Dow, E. ^{[10
]}

Ortuzar, W. ^{[11
]}

Buell, J. S. ^{[12
]}

Stein, R. B. ^{[13
]}

Youssoufian, H. ^{[7
]}

机构：

[1] Icon Canc Care, Clin Trials, South Brisbane, Australia

[2] Scientia Clin Res Sydney, Clin Trials, Randwick, NSW, Australia

[3] Linear Clin Res, Clin Trials, Perth, WA, Australia

[4] Agenus Bio Inc, Tcell Biol, Lexington, MA USA

[5] Agenus Bio Inc, Translat Med, Lexington, MA USA

[6] Agenus Bio Inc, Med Oncol, Lexington, MA USA

[7] Agenus Bio Inc, Clin Operat, Lexington, MA USA

[8] Agenus Bio Inc, Biostat & Data Management, Lexington, MA USA

[9] Agenus Bio Inc, Program & Portfolio Management, Lexington, MA USA

[10] Agenus Bio Inc, Dev Management, Lexington, MA USA

[11] Agenus Bio Inc, Corp Commun, Lexington, MA USA

[12] Agenus Bio Inc, Commun & External Affairs, Lexington, KY USA

[13] Agenus Bio Inc, Res Management, Lexington, MA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1168P

引用

页码：417 / 417

页数：1